The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic implications of TAMs in colorectal cancer hepatic metastases.
 
Matthew Reilley
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Riham Katkhuda
No Relationships to Disclose
 
Nicolle Patterson
No Relationships to Disclose
 
Tenghui Chen
No Relationships to Disclose
 
Jorge M Blando
No Relationships to Disclose
 
David Menter
No Relationships to Disclose
 
Dipen M. Maru
No Relationships to Disclose
 
James Patrick Allison
Patents, Royalties, Other Intellectual Property - Inventor of a patent held by the University of California, Berkeley, and licensed to Bristol Meyers-Squibb; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Genentech; Merrimack; MolecularMatch; Roche; Sanofi; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Padmanee Sharma
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merrimack; Roche/Genentech; sirtex Medical
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche